Jubilant Pharmova Ltd.

Financial

	Jubilant Pharmova	Alembic Pharma	Natco Pharma
Operational Metrics
Pharmaceutical Sector
Australia DMF fillings	14.0 .	n/a	n/a
Number of ANDA's Filed in Europe	38.0	21.0	n/a
Number of ANDA's Approved in Europe	37.0	19.0	n/a
Number of ANDA's Filed in Canada	24.0	21.0	n/a
Number of ANDA's Approved by Canada	24.0	20.0	n/a
Number of ANDA's Filed in USA	100.0 .	266.0 .	51.0 .
Number of ANDA's Approved By USFDA	62.0 .	220.0 .	41.0 .
US DMF Filings	98.0 .	140.0 .	58.0 .
Canada DMF fillings	42.0 .	n/a	n/a
Japan DMF Filings	15.0 .	n/a	n/a
R&D as a % of Total Sales	0.33 %	9.0 %	7.6 %
Financials
5 yr Average ROE	8.35 %	12.89 %	13.06 %
5yr average Equity Multiplier	2.0	1.39	1.18
5yr Average Asset Turnover Ratio	0.59	0.86	0.46
5yr Avg Net Profit Margin	7.13 %	11.15 %	23.09 %
Price to Book	2.85	3.67	2.05
P/E	21.23	32.69	8.29
5yr Avg Cash Conversion Cycle	-19.21 Days	9.46 Days	10.54 Days
Inventory Days	81.78 Days	99.1 Days	99.95 Days
Days Receivable	51.11 Days	66.32 Days	86.16 Days
Days Payable	173.51 Days	164.9 Days	154.15 Days
5yr Average Interest Coverage Ratio	3.98	30.59	46.61
5yr Avg ROCE	9.05 %	15.26 %	16.05 %
5yr Avg Operating Profit Margin	18.69 %	17.29 %	30.17 %
5 yr average Debt to Equity	0.64	0.14	0.06
5yr CAGR Net Profit	-38.8 %	-12.64 %	24.68 %
5yr Average Return on Assets	4.23 %	9.32 %	11.07 %
Shareholdings
Promoter Holding	50.68 %	69.67 %	49.56 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.0	0.06 %	0.75 %
Change in Mutual Fund Holding (3 Yrs)	3.61 %	4.02 %	-5.54 %

Business

	Jubilant Pharmova	Alembic Pharma	Natco Pharma
Product Wise Break-Up	Product Wise Break-Up Radiopharmaceuticals 44.9 Contract Manufacturing 16.81 Solid dosage formulations 10.82 Anti-allergic 10.21 Active Pharmaceutical Ingredient (API) 9.26 Contract Research and Development Services 6.7 India branded pharmaceuticals 0.72 Nutritional products 0 Specialty intermediates 0 Life science chemicals 0 Formulations 0 API 0 Crop Health 0 API(Domestic & Exports) 0 Formulation 0 Others 0.58	Product Wise Break-Up Radiopharmaceuticals 0 Active Pharmaceutical Ingredient (API) 0 Solid dosage formulations 0 Anti-allergic 0 India branded pharmaceuticals 0 Nutritional products 0 Specialty intermediates 0 Life science chemicals 0 Formulation 0 Contract Manufacturing 0 API(Domestic & Exports) 0 Crop Health 0 0 Formulations 80.68 Active Pharmaceutical Ingredient (API) 19.32	Product Wise Break-Up Radiopharmaceuticals 0 Active Pharmaceutical Ingredient (API) 0 Solid dosage formulations 0 Anti-allergic 0 India branded pharmaceuticals 0 Nutritional products 0 Specialty intermediates 0 Life science chemicals 0 Formulations 89.5 Contract Manufacturing 0 Active Pharmaceutical Ingredient (API) 3.6 Crop Protection 1.2 0 Formulations 0 API 0 Others 5.7
Segment Break-Up	Segment Break-Up Radiopharma 45.67 CDMO Sterile Injectables 18.99 Drug discovery and development solutions 17.52 Allergy Immunotherapy 9.79 Generics 8.03 Proprietary Novel Drugs 0 Life Science Ingredients 0 Pharmaceuticals 0 Agrochemicals 0	-	Segment Break-Up Pharmaceuticals 98.77 Life Science Ingredients 0 Agrochemicals 1.23 0 Radiopharma 0 Proprietary Novel Drugs 0 Generics 0 Allergy Immunotherapy 0 CDMO Sterile Injectables 0
Location Wise Break-Up	Location Wise Break-Up Americas and Europe 90.17 Rest of the World 7.5 India 2.33 China 0 USA 0	Location Wise Break-Up Americas and Europe 0 Rest of the World 60.12 India 39.88 USA 0 China 0	Location Wise Break-Up Americas and Europe 0 Rest of the World 15.24 India 14.27 USA 70.49 China 0
Operating Profit Break-Up	Operating Profit Break-Up Radiopharma 32.37 Allergy Immunotherapy 26.93 CDMO Sterile Injectables 23.64 Contract Research and Development 17.05 Generics 0 Proprietary Novel Drugs 0 Life Science Ingredients 0 Pharmaceuticals 0 Agrochemicals 0 Others 0.01	-	Operating Profit Break-Up Pharmaceuticals 100.0 Life Science Ingredients 0 Agrochemicals 0 Radiopharma 0 Proprietary Novel Drugs 0 Generics 0 Allergy Immunotherapy 0 CDMO Sterile Injectables 0 Contract Research and Development 0
Capex	Capex CDMO 58.69 Radiopharma 20.6 Contract Research and Development 15.56 Generics 2.12 Allergy Immunotherapy 1.54 Proprietary Novel Drugs 1.49 Life Science Ingredients 0	-	-
Asset Break-Up	Asset Break-Up Contract Research and Development 13.69 Proprietary Novel Drugs 2.12 Life Science Ingredients 0 Pharmaceuticals 0 Agrochemicals 0 Others 84.19	-	Asset Break-Up Pharmaceuticals 95.22 Life Science Ingredients 0 Agrochemicals 4.78 Proprietary Novel Drugs 0 Contract Research and Development 0

Jubilant Pharmova Ltd.

SIGN UP FOR FREE